Cancer Biomarkers Market Trends

  • Report ID: 4552
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Cancer Biomarkers Market Trends

Growth Drivers

  • Growing Prevalence of Cancer – Cancer prevalence is defined by how often cancer occurs (incidence rate) and how long a person lives with it after diagnosis (survival rate). Thus, the most common cancer with the longest survival rate will have a high prevalence value. For instance, breast cancer in women and prostate cancer in men had high prevalence rates with 42% and 43% in 2019, as per estimations throughout the world.
  • Elevating R & D Activities and Investments – For instance, the global cancer research and development activities continued to surge in 2021 with an increase of 50% more trail starts from 2021.
  • Increasing Biotechnology and Pharmaceutical Companies – Between 2017 to 2018, about 46 new molecular entities and 59 biologic license applications were approved by the U.S Food and Drugs Administration, and in 2019, out of the 59 newly approved drugs, 19 were first-in-class drugs. Also, the contracts worth for biotech and pharmaceutical companies are estimated to reach USD 150 billion before the first quarter of 2019 in the U.S.
  • Rising Use of Biomarkers in the Medical Sector – As per the observations, more than 50% of clinical trials used biomarkers in 2018, up from over 10% use in 2000 across the globe.
  • Increasing New Drug Developments – Based on a drug development report, FDA-approved biomarkers such as activating mutations in epithelial growth factor receptors (EGFR) can predict the efficiency of EGFR inhibitors, such as gefitinib, a targeted cancer drug. The response rate for gefitinib was more than 60% in selected patients and about 25% in unselected patients.

Challenges

  • The Dearth of Reimbursement Policies for Biomarker Testing - Even though there has been a surge in cancer incidences across the globe, and an escalating patient pool that needs a diagnostic test, and on the other hand, there is a deficit of reimbursement policies in numerous developed and developing countries, which is anticipated to hinder the growth of the cancer biomarkers during the forecast period of 2023-2033.
  • Requirement of Hefty Capital Investment for Research and Development Activities
  • Associated Issues in the Collection and Storage of Samples

Cancer Biomarkers Market: Key Insights

Base Year

2022

Forecast Year

2023-2033

CAGR

~14%

Base Year Market Size (2022)

~ USD 13 Billion

Forecast Year Market Size (2033)

~ USD 33 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Base Year

2024

Forecast Year

2025-2037

CAGR

13.7%

Base Year Market Size (2024)

USD 16.8 billion

Forecast Year Market Size (2037)

USD 90.3 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4552
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of cancer biomarkers is evaluated at USD 18.65 billion.

The cancer biomarkers market size was over USD 16.8 billion in 2024 and is anticipated to exceed USD 90.3 billion by the end of 2037, growing at over 13.7% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of cancer, elevating R & D activities and investments, rising use of biomarkers in the medical sector will boost the market growth.

North America industry is expected to dominate largest revenue share by 2037, due to rising population count & growing research activities, followed by the surging ratio of health insurance covering various cancer biomarker diagnoses in the region.

The major players in the market include INOVIQ, Bio-Rad Laboratories, Inc., Abbott Laboratories, Becton, Dickinson and Company, Merck KGaA, CENTOGENE GmbH, PerkinElmer Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Bristol Myers Squibb Company (BMS).
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample